B
Bullisch
Bullisch · 25%EVH
$10.23
Szenariopreis
$4.870
+0.144 (+2.96%)Zum Schluss
Loading chart…
- Hoch
- 5.115
- Eröffnung
- 4.750
- Volumengewichteter Durchschnittskurs
- 4.91
- Volumen
- 3.84M
- Marktkap.
- 2.30B
- Tief
- 4.750
- Umsatz
- 18.85M
- EV/EBITDA, TTM
- 20.06
Evolent Health, Inc. is a health care company connecting care for people with complex conditions like cancer, cardiovascular disease, and musculoskeletal diagnoses. The Company offers primary solutions, including specialty care management services and administrative services. It provides comprehensive quality management for oncology and cardiology patients from diagnosis through advanced care planning services, as well as identifying quality, lowest cost of care for outpatient orthopedic surgeries. Its administrative services solution includes an integrated value-based care platform designed to help customers manage and administer patient health in a cost-effective manner.
KI-Analyse of Evolent Health Inc (EVH)
KaufenEvolent Health Inc is a good buy right now, as it is currently priced at $4.04 with a 5-day change of +16.76%, indicating positive momentum. The forward P/E ratio is 8.62, suggesting it is undervalued compared to its earnings potential. However, the main risk is its high net debt-to-EBITDA ratio of 7x, which could lead to challenges in raising capital if market conditions worsen.
Analystenbewertungen (13)
+91.58% Aufwärtspotenzial
Kaufen
13 Kaufen
0 Halten
0 Verkaufen
Aktuell: 4.87
Tief
5.00
Durchschnitt
9.33
Hoch
16.00
Citi
Kaufen
$6
2026-08-10
Citi
2026-08-10
Kursziel
$6
Kaufen
Canaccord
Kaufen
$6
2026-08-10
Canaccord
2026-08-10
Kursziel
$6
Kaufen
TD Cowen
Kaufen
$5
2026-07-28
TD Cowen
2026-07-28
Kursziel
$5
Kaufen
Citi
Neutral
—
2026-07-23
Citi
2026-07-23
Kursziel
—
Neutral
Canaccord
Kaufen
$7
2026-07-21
Canaccord
2026-07-21
Kursziel
$7
Kaufen
Bewertungskennzahlen
Das aktuelle erwartete KGV von Evolent Health Inc (EVH) beträgt 8.62, verglichen mit dem 5-Jahres-Durchschnitt von 73.95.
Alphio-AI-Kursszenarien für EVH
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Whales, die EVH halten
Event-Zeitleiste
News
9.510-09PRnewswireEvolent Health to Release Q3 2026 Financial Results on November 5
7.509-21PRnewswireExpanded Partnership Enhances Language Access Across Evolent's Network
7.509-21NewsfilterEvolent Expands Partnership with TransPerfect to Enhance Language Access
6.508-16Yahoo FinanceHealthcare Stock Investment Opportunities and Risks Analysis
2.008-13NASDAQ.COMEvolent Health (EVH) Q2 2026 Earnings Call Transcript
EVH FAQ – beantwortet von Alphio AI
Evolent Health, Inc. is a health care company connecting care for people with complex conditions like cancer, cardiovascular disease, and musculoskeletal diagnoses. The Company offers primary solutions, including specialty care management services and administrative services. It provides comprehensive quality management for oncology and cardiology patients from diagnosis through advanced care planning services, as well as identifying quality, lowest cost of care for outpatient orthopedic surgeries. Its administrative services solution includes an integrated value-based care platform designed to help customers manage and administer patient health in a cost-effective manner. It operates in the Healthcare sector (SERVICES-MANAGEMENT SERVICES industry).
Evolent Health Inc is a good buy right now, as it is currently priced at $4.04 with a 5-day change of +16.76%, indicating positive momentum. The forward P/E ratio is 8.62, suggesting it is undervalued compared to its earnings potential. However, the main risk is its high net debt-to-EBITDA ratio of 7x, which could lead to challenges in raising capital if market conditions worsen.
13 analysts cover EVH: 13 rate it Buy, 0 Hold and 0 Sell. The average price target is 9.33.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.